Omicia and LabCorp Collaborate to Offer Comprehensive Genomic Analysis Services for Next-Generation Clinical Trials

Omicia today announced that Omicia’s clinical next-generation sequencing (NGS) interpretation software will be used by Laboratory Corporation of America Holdings (LabCorp) for its clinical trials sequencing services. LabCorp’s broad menu of testing services, combined with Omicia’s flexible, powerful, and easy-to-use genome analysis platform, will allow the companies to provide a comprehensive suite of expert tools and services for incorporating genomic data into clinical trials. Omicia’s software allows users to quickly and easily annotate genomes, analyze variant data, and generate customized clinical reports for individual patients and research projects across a broad range of disease states and clinical trial designs. Customers can also store, analyze, and manage their clinical trial data within a highly secure environment.

“Demand for well annotated and meaningful biomarker data to guide clinical trial design and execution is on the rise,” said Mike Aicher, Omicia CEO. “By integrating our breakthrough Opal genomic interpretation software with LabCorp’s clinical trials sequencing services into a complete and comprehensive solution, the analysis of genomic data can be easily and effectively integrated within clinical trials.”

The Omicia/LabCorp collaboration addresses the growing demand for NGS-derived biomarker data. This effort also highlights LabCorp’s continued focus on biomarker development to support clinical trial activities. The collaboration will enable customers of both companies to easily integrate NGS data into clinical trials and carry out studies quickly, efficiently, and affordably.

Omicia provides a state-of-the-art genome analysis software suite using proprietary algorithms, scalable interpretation solutions, and curated pharmacogenomics modules and content, all within a secure, HIPAA-compliant analysis environment. Omicia also allows users to generate customizable clinical reports and accommodates various trial sizes and designs.

About Omicia, Inc.
Omicia delivers genome analysis solutions for research, diagnostic and clinical applications. Our market-leading software platform enables analysis, interpretation and reporting on genomic data to expedite diagnosis and improve medical outcomes. Omicia’s products are in use at more than 300 world-class academic and clinical institutions worldwide. By accelerating understanding of the genetic basis of disease, drug response and health, Omicia is unlocking the potential of individualized medicine. Headquartered in Oakland, California, Omicia was founded by renowned industry veterans with a deep understanding of technology, genomics and diagnostics. Investors include Artis Ventures, Bay City Capital, Casdin Capital, Buchanan Investments, Acadia Woods and Yuri Milner. For more information, visit

< Back to News & Events